1.Department of Pharmacology, School of Pharmaceutical Science, Shandong University, Jinan 250012, China;
2. Shandong Institute of Pharmaceutical Industry ,Shandong Provincial Key Laboratory of Chemical Drug, Jinan 250033, China
Abstract��
Objective The systemic toxicities of S-(-)-pantoprazole sodium in rats following intravenous injuction for 30 d were studied. Methods One hundred rats were divided randomly into 5 groups: vehicle control group, pantoprazole sodium control group and three S-(-)-pantoprazole sodium groups with different dosages, and received vehicle, pantoprazole sodium(80 mg·kg-1·d-1),S-(-)-pantoprazole sodium(80, 40 and 20 mg·kg-1·d-1) by i.v.via tail vein. Administrations were performed each day for consecutive 30 d. Haematological parameters, biochemical parameters, and histopathology analysis were determined at 30 d of treatments and 14 d after the withdrawal, respectively. Results The rats in the S-(-)-pantoprazole sodium group at 80 mg·kg-1·d-1 apperanced shortness of breath, unsteady gait, lying motionless and other symptoms. The levels of TC, Na+, Cl- in this group were significantly higher or lower than those in vehicle control group at 30 d(P��0.05), The change of these parameters regained to normal at 14 d after withdrawal. Conclusion: Intravenous administration of the S-(-)-pantoprazole sodium for 30 d at high dose could induce reversible damage to liver and electrolyte. The toxicity of S-(-)-pantoprazole sodium is similar with pantoprazole sodium at the same dosage.
DAI Xiao-Li-,
,
GUO Xiu-Li-*
.Systemic Toxicity of S-(-)-Pantoprazole Sodium in Rats following Intravenous Injection for 30 d[J] Chinese Pharmaceutical Journal, 2013,V48(13): 1060-1064
��
[1]
CHEN W D,ZHANG W,LIU W J,et al. Synthesis of(S)-(-)-pantoprazole sodium. Chin J Pharm (�й�ҽҩ��ҵ��־),2012, 43(11) : 881-882.
[2]
JIA J H,WANG M W,LU F Z, et al. Effect of( - )-pantoprazole magnesium on experimental gastric ulcer.J Shenyang Pharm Univ(����ҩ�ƴ�ѧѧ��), 2004, 21(3): 218-221.
[3]
JIA J H,WANG M W,CAO H, et al. Effects of(-)-pantoprazole magnesium on experimental duodenal ulcer .J Shenyang Pharm Univ(����ҩ�ƴ�ѧѧ��), 2004, 21(4): 294-296.
[4]
VIKAS G P, NITIN V P, HEMANT P T, et al. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease . World J Gastroenterol, 2006, 12(37): 6017-6020.
[5]
GUO F,LU H L,CHEN G, et al. Preclinical toxicologic studies of(L-) pantoprazole sodium.J Med Sci Centr South China(����ҽѧ��ѧ��־),2012,40(1):51-54.
[6]
YUAN B J, LIAO M Y, LI B. Drug Toxicological Method and Technic(ҩ�ﶾ��ѧʵ�鷽���뼼��). Beijing:Chemical Industry Press,2007.
[7]
ZHOU Z C.A Course in Toxicology(����ѧ�̳�). Beijing:Beijing University Medical Press,2006.
[8]
WANG Y, SHEN L Z,LI B. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Chin Pharm Aff(�й�ҩ��), 2009, 23(8): 813-816.
[9]
WANG M. Drug induced liver damage caused by traditional Chinese medicine.Chin J Misdiagn(�й�����ѧ��־),2006, 6(7): 1388-1390.
[10]
HYE Y J,HYE W L,HUI H K,et al. Characterization of human liver cytochrome p450 enzymes involved in the metabolism of a new H+/K+-ATPase inhibitor KR-60436. Toxicol Lett,2005, 155(1): 103-114.
[11]
SHIN J M,SACHS G.Differences in binding properties of two proton pump inhibitors on the gastric H+/K+-ATPase in vivo. Biochem Pharmacol,2004, 68(11): 2117-2127.
2013, Vol. 48 
